All In Biotech

Drug Trial Radar · NCT04534205

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

An Open-label Phase II/III Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 358 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

358

Actual

Start

Jan 7, 2021

Primary completion

Apr 2029

Study completion Apr 2029

Sponsor

Lead sponsor
BioNTech SEIndustry
Sponsor type
Industry
First posted
Sep 1, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open-label, controlled, multi-site, interventional, 2-arm, Phase II/III trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in patients with unresectable recurrent or metastatic HPV16+ HNSCC expressing programmed cell death ligand-1 (PD-L1) with combined positive score (CPS) ≥1. This trial has two parts. Part A, is an initial non-randomized Safety Run-In Phase to confirm the safety and tolerability at the selected dose range level of BNT113 in combination with pembrolizumab. Part B, is a randomized part to generate pivotal efficacy and safety data of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy in the first line setting in patients with unresectable recurrent or metastatic HPV16+ HNSCC expressing PD-L1 with CPS ≥1. Patients included in the Safety Run-In Phase of the trial (Part A) will not be randomized to Part B and will continue on-trial treatment (BNT113 plus pembrolizumab) within Part A. For Part B, an optional pre-screening phase is available for all patients where patients' tumor samples may be submitted for central HPV16 DNA and central PD-L1 expression testing prior to screening into the main trial. Patients will be treated with BNT113 in combination with pembrolizumab or with pembrolizumab monotherapy for approximately up to 24 months.

Conditions

  • Unresectable Head and Neck Squamous Cell Carcinoma
  • Metastatic Head and Neck Cancer
  • Recurrent Head and Neck Cancer

Interventions

  • BNT113Biological

    IV injection

  • PembrolizumabBiological

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A - Occurrence of treatment-emergent adverse event (TEAE) - BNT113 in combination with pembrolizumabTime frame: up to 27 months
  2. Part B - Overall survival (OS)Time frame: up to 48 months
  3. Part B - Progression-free survival (PFS)Time frame: up to 48 months

Locations

136 sites in 21 countries. Site status is shown where the registry gives one.

  • UCLA Cancer Care

    Los Angeles, California

  • Stanford Cancer Institute

    Palo Alto, California

  • Yale University

    New Haven, Connecticut

  • The George Washington Cancer Center

    Washington D.C., District of Columbia

  • University of Miami Miller School of Medicine

    Miami, Florida

  • Winship Cancer Institute

    Atlanta, Georgia

  • Norton Cancer Institute

    Louisville, Kentucky

  • Tufts Medical Center

    Boston, Massachusetts

  • Massachusetts General Hospital

    Boston, Massachusetts

  • The University of New Mexico Comprehensive Cancer Center

    Albuquerque, New Mexico

  • Memorial Sloan Kettering Cancer Center

    Long Island City, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Montefiore Medical Center

    The Bronx, New York

  • University of Cincinnati Cancer Center

    Cincinnati, Ohio

  • MD Anderson Cancer Center

    Houston, Texas

  • Centro de Oncología e Investigación Buenos Aires COIBA

    Berazategui, Argentina

  • Instituto de Oncologia de Cordoba

    Córdoba, Argentina

  • Centro Oncologico Riojano Integral

    La Rioja, Argentina

  • Centro de Investigacion Pergamino SA - Clinica Pergamino

    Pergamino, Argentina

  • Instituto de Oncologia de Rosario

    Rosario, Argentina

  • Sanatorio Britanico

    Rosario, Argentina

  • CAIPO Centro para la Atencion Integral del Paciente Oncologico

    San Miguel de Tucumán, Argentina

  • Cancer Research SA

    Adelaide, Australia

  • Flinders Medical Centre

    Bedford Park, Australia

  • St Vincent's Hospital

    Fitzroy, Australia

  • Royal North Shore Hospital

    Saint Leonards, Australia

  • John Flynn Private Hospital

    Tugun, Australia

  • Southern Medical Day Care Centre

    Wollongong, Australia

  • LKH - Univ. Klinikum Graz

    Graz, Austria

  • Landeskrankenhaus/ Univ.-Kliniken Innsbruck

    Innsbruck, Austria

  • HNO, Kopf-und Halschirurgie Ordensklinikum Linz Barmherzigen Schwestern

    Linz, Austria

  • Uniklinikum Salzburg, Univ. Klinik fur Innere Medizin III

    Salzburg, Austria

  • Universitair Ziekenhuis Brussel

    Brussels, Belgium

  • Universitair Ziekenhuis Gent UZ Gent

    Ghent, Belgium

  • Fundação PIO XII - Hospital de Amor Barretos

    Barretos, Brazil

  • Oncocentro - Grupo Oncoclinicas

    Belo Horizonte, Brazil

  • Fundacao Universidade de Caxias do Sul - Instituto de Pesquisas em Saude IPS-UCS

    Caxias do Sul, Brazil

  • Hospital Erasto Gaertner

    Curitiba, Brazil

  • Oncosite - Centro de Pesquisa Clinica em Oncologia

    Ijuí, Brazil

  • Hospital Marcio Cunha

    Ipatinga, Brazil

Showing 40 of 136 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.